Conference report: Roxadustat demonstrates non-inferiority to darbepoetin in phase III DOLOMITES study of anaemia in non-dialysis-dependent adult patients with chronic kidney disease

Study showed non-inferiority of roxadustat to darbepoetin alfa in the correction of haemoglobin levels during the first 24 weeks of treatment (89.5% vs 78.0%; a difference of 11.51% [95% Cl: 5.66-17.36%]), meeting the study's primary endpoint with a lower bound of the 95% CI >0.

Source:

Biospace Inc.